Article
The synergistic effect of CDKN2B-AS1 and SPC25 on triple-negative breast cancer
1 Jul 2022
Abstract excerpt
Background: Accumulating evidence suggests that long non-coding ribonucleic acid (RNA) cyclin-dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1) and messenger RNA (mRNA) spindle component 25 (SPC25) contribute to tumorigenesis and progression in various cancers. However, the synergistic effect between CDKN2B-AS1 and SPC25 has not yet been fully elucidated in triple-negative breast cancer (TNBC). This...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
